- The randomised phase 3 trial included 359 patients that were randomly assigned a single fusion of axi-cel or standard-of-care therapies for R/R large B-cell lymphoma
- Results showed a significant EFS improvement (HR = 0.39; P<0.0001) among patients assigned axi-cel
- Axi-cel also exhibited a safety profile consistent with that observed with use of the agent in the third-line setting
to learn more.
SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.
DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.
For more information, please visit www.svmpharma.com
and contact us at firstname.lastname@example.org